⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ROIV News
Roivant Sciences Ltd. Common Shares
Form 8-K
sec.gov
ROIV
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
globenewswire.com
ROIV
IMVT
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
globenewswire.com
ROIV
ROIVW
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
globenewswire.com
ROIV
ROIVW
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
globenewswire.com
ROIV
ROIVW
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
globenewswire.com
ROIV
ROIVW
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
globenewswire.com
IMVT
ROIV
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
globenewswire.com
ROIV
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
globenewswire.com
ABUS
ROIV
PFE
BNTX
MRNA
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight
globenewswire.com
IMVT
ROIV
MRK
NVS
REGN
UCB
JNJ
ARGX
AMGN
VIR
IPHA
ARWR
APLS
CABA